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Effects of human soluble thrombomodulin on experimental Thrombus formation and fibrin deposition in glomeruli
glomerulonephritis. are the important pathologic processes of glomerular in-
Background. Coagulation and inflammation are both impor- jury [1–3]. In fact, glomerular thrombi are often found intant processes that contribute to glomerular injury. The present
human glomerulonephropathies [2, 4, 5]. In normal con-study was performed to evaluate the effects of recombinant hu-
man soluble thrombomodulin (RHS-TM) in a lethal model of ditions, thrombus formation does not occur, since endo-
thrombotic glomerulonephritis and to investigate the possible thelial cells are protected by anti-thrombotic factors such
mechanisms. as prostaglandin I2, nitric oxide, anti-thrombin III, tissueMethods. Thrombotic glomerulonephritis was induced in rats
factor pathway inhibitor, and thrombomodulin (TM) [6].by administration of lipopolysaccharide and rabbit anti-rat glo-
However, when endothelial cells are damaged, they losemerular basement membrane antibody. One hour later, RHS-TM
or heparin was administered, and the histological findings, renal their anti-thrombotic properties resulting in thrombus for-
functions, and coagulation parameters were evaluated. To eval- mation [6].
uate the contribution of carboxypeptidase R (CPR) to the re-
Thrombomodulin is a cell surface glycoprotein thatsults obtained in rats treated with RHS-TM, plasma CPR levels
forms a 1:1 complex with thrombin [7, 8]. Once this com-were measured. Then, carboxypeptidase inhibitor (CPI), which
prevents the function of CPR, was administered. plex is formed, thrombin loses its ability to convert fibrin-
Results. Massive glomerular thrombosis and lung hemorrhage ogen to fibrin and enhances its capacity to activate protein
developed within five hours of disease induction, and all rats
C [8–10]. This leads to the decrease of factor Va level,died within 24 hours. RHS-TM (3 mg/kg) prevented the pro-
inhibition of thrombin generation, and prolongation of thegression of the disease and all rats survived. Heparin (250
U/kg/h) showed similar anti-thrombotic effect, but induced clotting time [11]. In the kidney, TM is expressed mainly
massive hemorrhage in the lungs or stomach. RHS-TM attenu- on the endothelial cells, and it increased in the patients
ated leukocyte/neutrophil infiltration in the glomerulus but with lupus nephritis or membranoproliferative glomerulo-heparin did not, suggesting that RHS-TM has anti-inflamma-
nephritis [12]. In these diseases, thrombus formation is ob-tory properties. CPR levels in plasma were about threefold
higher in rats treated with RHS-TM compared to those in rats served frequently. It was supposed that TM expression was
treated with heparin. Furthermore, the inhibitory effect of RHS- enhanced in order to protect the kidney from thrombotic
TM on leukocyte/neutrophil infiltration was significantly dimin- injuries while its increase was not enough to inhibitished by injection of CPI.
thrombosis. It is assumed that relative insufficiency inConclusion. RHS-TM effectively attenuates the injuries of
TM activity allows thrombus formation. Therefore, ad-thrombotic glomerulonephritis in rats. The results indicate that
RHS-TM, in addition to its anti-thrombotic action, may exert ministration of soluble TM [11, 13, 14] or overexpression
its anti-inflammatory properties by converting proCPR to CPR, of TM on the endothelial cell surface [15] is expected towhich then inactivates anaphylatoxins. RHS-TM is a potential
prevent thrombosis.novel therapeutic tool for thrombotic glomerular injury and re-
A human TM cDNA clone was isolated and recombi-lated disorders.
nant human soluble TM (RHS-TM) has been produced in
Chinese hamster ovary cells [11, 16, 17]. In animal modelsKey words: thrombin, anticoagulant, kidney, carboxypeptidase, ana-
phylatoxin, glomerular injury, inflammation. of disseminated intravascular coagulation, RHS-TM has
been proved to be effective [11, 13, 14]. The presentReceived for publication July 2, 2001
work was designed to evaluate the effect of RHS-TM inand in revised form September 18, 2001
Accepted for publication September 19, 2001 comparison with heparin and to investigate the possible
mechanisms using a rat model of thrombotic glomerulo- 2002 by the International Society of Nephrology
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nephritis [18]. The pathology of this model resembles Co., Ltd. (Tokyo, Japan). Heparin sodium was obtained
that of thrombotic thrombocytopenic purpura and he- from Green Cross Co., Ltd. (Tokyo, Japan). Lipopoly-
molytic uremic syndrome, which are difficult diseases to saccharide (LPS) prepared from phonolic extracts of
treat in the clinical setting and have a relatively high Salmonella typhimurium, and potato carboxypeptidase
mortality. inhibitor (CPI), an inhibitor of carboxypeptidase A
The data obtained in this work revealed that RHS-TM and CPR, were obtained from CalBiochem (La Jolla,
has great therapeutic potential. The results also demon- CA, USA).
strated that, in addition to its anti-thrombotic properties,
RHS-TM has anti-inflammatory effects. The thrombin- Experimental model
TM complex not only activates protein C, but it can also Thrombotic glomerulonephritis was induced in rats
convert proCPR, the precursor of carboxypeptidase R according to a modified method of Tomosugi et al [18].
(CPR) [19, 20], to CPR. ProCPR is identical to and also is Briefly, a mixture of 2.5g of LPS and 5 mg of A-GBMAb
referred to as thrombin-activatable fibrinolysis inhibitor in 0.5 mL of physiological saline was injected via tail
[21–24]. By removing the terminal arginine residues, vain. Intravenous injection of 2.5 g of LPS alone did
CPR suppresses fibrinolysis and degrades and inactivates
not induce any clinical symptoms or histological changes.
anaphylatoxins, C3a and C5a [25, 26]. Since we have
Five milligrams of A-GBM induced only mild cellularrecently shown that the glomerular injury in this model
infiltration in glomeruli. However, simultaneous injec-is partially dependent on C5a [27], we focused on those
tion of LPS and A-GBM induced cellular infiltration ineffects of CPR. Details of the experiments and the possi-
glomeruli at one hour, and severe glomerular injury withble mechanisms of RHS-TM are discussed in this article.
massive thrombotic reaction within five hours after in-
duction of disease. Diffuse spotted lung hemorrhage was
METHODS also observed. All rats died within 24 hours.
Animals
ProtocolsFemale Wistar rats (150 to 170 g) and Japanese white
Experiment 1. The first experiment was performed inrabbits (2.5 to 2.7 kg) were purchased from Chubu Ka-
order to evaluate the effects of RHS-TM during thegaku Shizai Co. Ltd. (Nagoya, Japan). Rats were housed
early phase (5 hours) of the present model. Rats wereindividually in metabolic cages with free access to water
divided into six groups and treated as described below.and food throughout the experiments. These experiments
were performed according to the Animal Experimenta- Group 1-I comprised the positive controls where a mix-
tion Guide of Nagoya University School of Medicine. ture of 2.5 g of LPS and 5 mg of A-GBMAb/head was
injected intravenously. Group 1-II rats had 1 mg/kg of
Reagents RHS-TM administered intravenously one hour after the
The rat glomerular basement membrane (GBM) was injection of LPS and A-GBMAb. Group 1-III animals
prepared according to the method described before [28]. had 3 mg/kg of RHS-TM administered intravenously one
Rabbit anti-rat GBM antisera were produced in rabbits hour after induction of disease. In group 1-IV and 1-V
by subcutaneous immunization of rat GBM in complete rats, heparin was administered in two different doses
Freund’s adjuvant every two weeks. Rabbits were bled and the effects were compared with RHS-TM. Group
32 days after the first immunization. Complements were 1-IV had heparin continuously infused from the jugular
inactivated by incubating with anti-sera at 56C for 30 vein for four hours using a syringe pump (Termo Medical
minutes. The -globulin fraction was obtained by ammo- Corp., Tokyo, Japan) starting at one hour after disease
nium sulfate precipitation, and used as anti-GBM antibody
induction at the rate of 83 U/kg/h. Over this period, a
(A-GBMAb) for the study [29]. A mouse monoclonal
total amount of 333 U of heparin in 4 mL of saline wasantibody against rat leukocyte common antigen (LCA)
administered to a rat. Group 1-V animals had heparinwas purchased from Serotec (Indianapolis, IL, USA).
continuously infused starting at one hour after diseaseRP-3, a specific mouse monoclonal antibody against rat
induction at the rate of 250 U/kg/h. A total amount ofneutrophils, was a gift from Professor F. Sendoh (Yama-
1000 U was administered in this group. Group 1-VI weregata University School of Medicine, Yamagata, Japan)
the normal controls. Saline was administered instead of[30–32]. FITC-conjugated mouse antibody to human fi-
LPS, A-GBMAb, and RHS-TM. All rats were anesthe-brinogen, which cross-reacted with rat fibrin, was pur-
tized and killed at five hours after disease induction forchased from Organon Teknika Corporation (Durham,
the study.NC, USA). FITC-conjugated rabbit anti-mouse IgG,
Experiment 2. To study the effects of RHS-TM on thegoat anti-mouse IgM, rabbit anti-rat C3 and goat anti-
mortality, rats were divided into two groups as describedrabbit IgG were from Cappel Laboratories (Cochran-
ville, PA, USA). RHS-TM was obtained from Asahi Kasei below. Group 2-I were administered a mixture of 2.5 g
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Table 1. Experimental protocol
Group Number of rats LPSA-GBM Treatment Observation period hours
Experiment 1
1-I 6 () Saline (positive control)a 5
1-II 6 () RHS-TM 1 mg/kga 5
1-III 6 () RHS-TM 3 mg/kga 5
1-IV 6 () Heparin 83 U/kg/hb 5
1-V 6 () Heparin 250 U/kg/hb 5
1-VI 6 () Saline (normal control)a 5
Experiment 2
2-I 6 () Saline (positive control)a 24c
2-II 6 () RHS-TM 3 mg/kga 24
Experiment 3
3-I 4 () Saline (normal control)a 5
3-II 4 () RHS-TM 3 mg/kga 5
3-III 4 () Saline (positive control)a 5
3-IV 4 () Heparin 250 U/kg/h 5
3-V 4 () RHS-TM 3 mg/kga 5
Experiment 4
4-I 6 () RHS-TM 3 mg/kga
Salined 5
4-II 6 () RHS-TM 3 mg/kga
CPId 5
4-III 6 () CPId 5
Abbreviations are: RHS-TM, recombinant human soluble thrombomodulin; LPS, lipopolysacharride; A-GBM, anti-glomerular basement membrane; CPI, carboxy-
peptidase inhibitor.
a Single injection
b Continuous infusion for 4 hours
c All rats died within 24 hours
d Hourly injection from 1 to 4 hours
of LPS and 5 mg of A-GBMAb/head intravenously and less than 0.24 ng/head. This shows that LPS contamina-
tion was minimal. Rats in Group 4-I were treated simi-saline was injected one hour later. Group 2-II only had
a single dose (3 mg/kg) of RHS-TM given intravenously larly to those in Group 4-II, but saline was administered
instead of CPI plus saline. In Group 4-III, CPI was in-one hour after the LPS and A-GBMAb injection. These
rats were observed for 24 hours after induction of the jected into normal control rats with the same protocol
as that of Group 4-II. Rats were euthanized at five hoursdisease, and surviving rats were euthanized at the end
of the experiment. for the evaluation of leukocyte infiltration into glomeruli.
The experimental protocols are summarized in Table 1.Experiment 3. The experiment was performed to mea-
sure CPR activities in circulation. Saline (Group 3-I) or
Histological and immunohistological evaluation3 mg/kg RHS-TM (Group 3-II) was intravenously injected
to the normal rats. In positive control rats (Group 3-III), At the end of the experiments, kidney tissue was har-
vested for histological and immunohistological evalua-saline was injected one hour after LPS and A-GBMAb
injection. Group 3-IV and 3-V, while heparin (Group tion. The other organs were just macroscopically exam-
ined. For light microscopy, methacaln fixed and paraffin3-IV) or RHS-TM (Group 3-V) was administered using
the same protocol as in Group 1-V and 1-III, respectively. embedded sections cut at 2 mm thick were stained with
periodic acid-Schiff (PAS) reagent. For immunohistolog-Plasma was prepared with trisodium citrate and kept at
70C until measurement. ical evaluation, another part of specimen was embedded
in OCT compound (Miles, Elkhart, IN, USA) and snapExperiment 4. The experiment was performed to in-
vestigate the possible contribution of CPR to the anti- frozen in liquid nitrogen. It was kept at 70C until use.
Two-millimeter thick sections were cut using a cryostatinflammatory effects of RHS-TM in this model. In Group
4-II, 100 g/kg CPI dissolved in 200 L of saline was ad- and fixed in acetone for ten minutes at room tempera-
ture. The sections were immunostained for fibrinogen,ministered intraperitoneally six times hourly beginning
one hour before the injection of LPS and A-GBMAb. leukocytes (LCA positive cells), neutrophils (RP-3 posi-
tive cells), rabbit IgG and rat C3 by the methods de-Then, 3 mg/kg RHS-TM was given one hour after disease
induction. The dose of CPI was determined according scribed elsewhere [34, 35].
For the evaluation of thrombus formation, PAS stainedto the previous report [33]. Endotoxin was removed from
commercially available CPI using polymixin B column sections were examined by the light microscopy in a semi-
quantitative manner. Fifty randomly selected glomeruli(Detoxi-Gel; Pierce, Rockford, IL, USA). The total
amount of LPS in the CPI preparation administered was cut along the equator were observed. In each glomerulus,
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Fig. 1. Light microscopic finding of the representative glomerulus. Massive thrombus formation was observed in a positive control rat (Group
1-I; A). Recombinant human soluble thrombomodulin (RHS-TM; B) or heparin in a smaller dose (Group 1-IV; D) reduced thrombus formation
considerably. Three mg/kg of RHS-TM (Group 1-III; C) completely inhibited the change. Heparin in a larger dose (Group 1-V; E) had a comparable
effect (magnification 400).
the ratio of glomerular capillary area filled with thrombi time (PT) and activated partial prothrombin time (APTT)
were measured by Special Reference Laboratories (SRLto the total glomerular capillary area was evaluated and
glomeruli were graded into five ranks:5%, 5 to 25%, 26 Co. Ltd., Tokyo, Japan). One milliliter of blood was
collected into a plastic tube containing EDTA-2K, andto 50%, 51 to 75%, and75%. The number of glomeruli
belonging to each rank was processed to represent the platelets were also counted by SRL Co. Ltd. The rest of
the blood was collected into a glass tube, placed over-profile of thrombus formation in each group.
For the evaluation of infiltrating leukocytes and neu- night and centrifuged at 1500 rpm for 10 minutes. Serum
creatinine and blood urea nitrogen (BUN) were mea-trophils, LCA and RP-3 positive cells were counted in
50 randomly selected glomeruli cut along the equator. sured using a Cre-Kainos kit (Kainos Co. Ltd., Tokyo,
Japan) and an Iatrochrom UN kit (Iatron Co. Ltd.,The average number per glomerular cross section was
used as a representative value for each rat. The histologi- Tokyo, Japan), respectively.
cal evaluation and cell counts were performed by two
Measurement of CPR levelsinvestigators who were blinded to the origin of the cells.
First, activity of total carboxypeptidase in fresh plasma,
Coagulation parameters, serum creatinine, and which consisted of carboxypeptidase N and CPR [20], was
blood urea nitrogen measured by the method described previously [36–38].
Briefly, 20 L of plasma and 40 L of 30 mM hippuryl-At the end of the experiment, 4.0 mL of blood was col-
lected from the abdominal aorta. Then, 1.8 mL of blood l-arginine in 50 mM HEPES (pH 8.2) as the substrate
solution were incubated at 37C for 45 minutes, andwas transferred into a plastic syringe containing 0.2 mL
of 3.8% trisodium citrate, and plasma was prepared by 20 L of 2.5 M HCl were added to stop the enzyme
reaction. After extraction with 300 L ethyl acetate, thecentrifugation at 3000 rpm for 10 minutes. Prothrombin
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Fig. 2. Immunofluorescent staining for fibrin of the representative glomerulus. Positive control rats had marked fibrin deposition (Group 1-I; A).
RHS-TM or heparin in a smaller dose (Group 1-II; B; Group 1-IV, D) reduced fibrin deposition significantly. In rats treated with a larger dose
of RHS-TM (Group 1-III; C ), no staining was observed. Rats infused with heparin (Group 1-V; F ) had only trace staining (400).
top 200L was removed and evaporated, and the residue RESULTS
was dissolved in 200 L of double-distilled water. The Experiment 1
OD228 of the reaction product (hippuric acid) was com- Effects of RHS-TM on the thrombus formation and fibrin
pared to that of dilutions of a standard solution of hip- deposition in glomeruli. In the positive control (Group
puric acid. Next, carboxypeptidase activity in 20 L 1-I), all glomeruli were filled with fresh thrombi that oc-
plasma mixed with 1 L of CPI (CalBiochem) solution cupied most of glomerular capillary lumen (Fig. 1A).
(adjusted to 1 mg/mL with 50 mM Tris buffer, pH 7.5) Fibrin was strongly stained in this area (Fig. 2A). In
was measured similarly. CPI inhibited CPR but not car- comparison, a marked reduction of thrombus formation
boxypeptidase N [38]. Therefore, subtraction of these was observed in the RHS-TM or heparin treated groups
two numbers corresponded to the level of CPR in (Group 1-II through 1-V; Figs. 1 B-E and 2 B-E). As
plasma. All measurements were done in triplicate. for RHS-TM, a single intravenous injection of 1 mg/
kg RHS-TM at one hour after injection of LPS and
Statistical analysis A-GBMAb significantly, but not completely, inhibited
All values are given as mean	 SE. One factor analysis thrombus formation and fibrin deposition in the glomer-
of variance (ANOVA) was used to determine the sig- uli (Group 1-II; Figs. 1B and 2B). The larger dose
nificant difference among groups. When statistical differ- (3 mg/kg) of RHS-TM completely inhibited these changes
ence existed by ANOVA, further analysis was performed (Group 1-III; Figs. 1C and 2C). Concerning heparin,
using the Fisher PLSD-test to determine the difference continuous infusion at a rate of 83 U/kg/h starting at one
between any pair of groups. Significant difference was hour after LPS and A-GBMAb injection partially inhib-
ited the thrombus formation (Group 1-IV, Figs. 1D andset when the P value was less than 5% (P  0.05).
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Fig. 3. Semiquantitative analysis of thrombus formation. All glomeruli were filled with thrombi that occupied most of glomerular capillary lumens
in the positive control (Group 1-I; A). One mg/kg RHS-TM significantly reduced thrombus formation (Group 1-II; B). Three mg/kg of RHS-TM
completely inhibited thrombosis (Group 1-III; C). Continuous infusion of heparin in the smaller dose did not inhibit the thrombosis completely
(Group 1-IV; D). Heparin in the larger dose (Group 1-V; E) had the comparable effect with 3 mg/kg of RHS-TM (Group 1-III; C).
2D), whereas continuous infusion of heparin in the larger that RHS-TM but not heparin had inhibitory effects on
leukocyte/neutrophil infiltration.dose (250 U/kg/h, Group 1-V) had comparable effects
to Group 1-III (Figs. 1E and 2E). Semiquantitative data Coagulation parameters, platelet counts and bleeding ten-
dency. Significant elongation of PT was observed only inare given in Figure 3.
Effects of RHS-TM on cellular infiltration. A signifi- rats infused with the larger dose of heparin (Group 1-V).
RHS-TM did not affect PT at four hours after injectioncant increase of LCA positive cells (total leukocytes) was
observed in all experimental groups compared to normal (Group 1-II and IV). APTT was prolonged in rats treated
with the larger dose of RHS-TM (Group 1-III) or thecontrol rats (Groups 1-I through 1-V vs. 1-VI). Among
these groups, rats treated with RHS-TM (Groups 1-II larger dose of heparin (Group 1-V). Rats injected with
the smaller dose of RHS-TM (Group 1-II) showed sig-and 1-III) showed significantly less infiltration of leuko-
cytes than Group 1-I rats (Fig. 4A). Since most of the nificantly shorter APTT compared to positive controls
(Group 1-I) or rats infused with the smaller dose ofinfiltrating cells were neutrophils during the acute phase
of this model [39], we evaluated the extent of neutrophil heparin (Group 1-IV). Platelet numbers were increased
in rats treated with RHS-TM or heparin (Group 1-IIinfiltration in the glomeruli. RHS-TM prevented neutro-
phil infiltration (Groups 1-II and 1-III; Fig. 4B). In con- through 1-V) compared to the positive control (Group
1-I; Table 2). Three out of six rats in Group 1-IV (heparintrast, heparin did not show the inhibitory effect on leuko-
cyte/neutrophil infiltration (Group 1-IV and 1-V). The 250 U/kg/h) and one out of six in Group 1-V (heparin
83 U/kg/h) showed moderate lung and gastrointestinalleukocyte/neutrophil count in rats treated with the larger
dose of heparin was rather higher than that of the normal hemorrhage. Rats treated with RHS-TM showed only
mild spotted hemorrhage in the lungs at five hours aftercontrol (Group 1-V; Fig. 4 B, C). These data indicated
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Fig. 4. Effects of RHS-TM on cellular infiltration. (A) Significant increase in leukocyte infiltration was seen in all experimental groups compared
to normal control rats (Groups 1-I through 1-V vs. 1-VI). RHS-TM decreased leukocyte counts (Groups 1-II and 1-III vs. 1-I). In contrast, rats
treated with the larger dose of heparin (Group 1-V) showed more leukocytes in the glomeruli than positive control rats (Group 1-I). (B) RHS-TM
suppressed neutrophil infiltration significantly (Group 1-II and 1-III vs. 1-1) while heparin increased neutrophil count in the glomeruli (Group
1-V vs. 1-I)
Table 2. Effect of RHS-TM and heparin on platelets, PT and APTT in experiment 1
Group Treatment Platelets (104) PT(s) APTT(s)
1-I Saline (positive control) 6.9	0.90 43.0	5.0 159.7	44.6
1-II RHS-TM 1 mg/kg 13.4	1.5 26.6	0.5 79.1	2.9c
1-III RHS-TM 3 mg/kg 35.5	6.4a 24.0	0.7 249.5	32.2d
1-IV Heparin 83 U/kg/h 17.6	2.9 31.0	4.5 144.3	32.8
1-V Heparin 250 U/kg/h 60.5	4.5a 170.0	58.2b 300.0d
1-VI Saline (normal rat) 80.6	7.0a 15.0	0.5 51.9	3.0
Abbreviations are in Table 1 and also: PT, prothrombin time; APTT, activated partial prothrombin time. Data are mean 	 SE.
a P  0.01 vs. group 1-I
b P  0.01 vs. groups 1-I, II, III, IV and VI
c P  0.01 vs. groups 1-I, III, IV and V
d P  0.01 vs. groups 1-I, II, IV and VI
induction of disease, and there was no gastrointestinal Experiment 2
hemorrhage. Thus, RHS-TM had a tendency to bleed Effects of RHS-TM on mortality. Rats injected with
less than heparin. LPS and A-GBM (Group 2-I) presented prominent lung
Serum BUN and creatinine levels. In the positive con- hemorrhage and they all died within 24 hours. In con-
trol (Group 1-I), BUN significantly increased to 42.5 	 trast, all rats treated with RHS-TM (Group 2-II) were
7.5 mg/dL. In the RHS-TM treated groups, serum BUN alive at 24 hours after disease induction, and hemor-
level was significantly lower. Although BUN level of rats rhages were not found.
treated with the smaller dose of heparin (Group 1-IV)
Experiment 3was not different from Group 1-I, rats treated with larger
dose of heparin (Group 1-V) showed a higher BUN CPR activities in plasma. Carboxypeptidase R activity
level than Group 1-I. Serum creatinine level was also in plasma was not detected in the circulation of normal
significantly increased to 1.39 	 0.16 mg/dL in the posi- control rats (Group 3-I), nor did RHS-TM alone increase
tive control (Group 1-I). The increase of serum creati- CPR levels (Group 3-II). CPR levels were elevated sig-
nine level was effectively inhibited by RHS-TM and high nificantly in positive control rats (Group 3-III), in which
dose, but not low dose, of heparin. The discrepancy be- abundant thrombin was generated, suggesting that proCPR
tween BUN and creatinine seen in Group 1-V was sup- was converted to CPR by endogenous TM and thrombin
posed to be derived from the presence of gastrointestinal complex formed in this group. A larger dose of heparin
that inhibited thrombus formation (Group 3-IV) de-hemorrhage in this group (Fig. 5).
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Fig. 5. Blood urea nitrogen (BUN) and serum creatinine levels. (A) In the positive control (Group 1-I), BUN significantly increased. In RHS-
TM treated rats, increase of BUN was significantly attenuated (Group 1-II and 1-III). In contrast, BUN levels of rats in heparin treated groups
(Group 1-IV and 1-V) were not different from Group I-1. (B) Serum creatinine levels were also significantly increased in the positive controls
(Group 1-I). In RHS-TM treated rats (Group 1-II and 1-III), creatinine elevation was inhibited. The larger dose of heparin (Group 1-V) also
inhibited the elevation, while the rats treated with smaller dose of heparin (Group 1-IV) had still elevated creatinine levels.
Experiment 4
Effects of CPR on cellular infiltration in the glomerulus.
Neutrophils were observed in the glomeruli of RHS-TM
treated rats (Group 4-I). The inhibitory effect of RHS-TM
on leukocyte/neutrophil infiltration was significantly di-
minished by the injection of CPI, an inhibitor of CPR,
but not carboxypeptidase N (Group 4-II). CPI alone did
not increase the leukocyte/neutrophil counts (Group 4-III;
Figs. 7 and 8).
DISCUSSION
Fig. 6. Carboxypeptidase R (CPR) levels in plasma. CPR activity was In the present study, a rat model of thrombotic glomer-
not detected in the normal controls (Group 3-I) or in rats injected with
ulonephritis induced by the simultaneous injection ofRHS-TM alone (Group 3-II). In positive control rats injected with LPS
and anti-glomerular basement membrane antibody (A-GBMAb; Group LPS and A-GBMAb was employed. Within one hour, sig-
3-III), CPR levels were elevated. Heparin infusion (Group 3-IV) re- nificant cellular infiltration, mainly composed of neutro-
duced this elevation significantly. In RHS-TM treated rats (Group 3-V),
phils, was observed accompanied by glomerular bindingCPR levels were increased about threefold as compared to those in
heparin treated rats (Group 3-IV; P  0.01). of A-GBMAb and rat C3. At five hours, massive throm-
bus formation, fibrin deposition, and prominent inflam-
matory cell infiltration were observed in all glomeruli.
The disease was fatal and all rats died within 24 hours.
creased the CPR levels by half (P 0.05). In rats injected Since rats developed massive glomerular thrombosis and
with the larger dose of RHS-TM following the disease lung hemorrhage, we assumed these to be the causes of
induction (Group 3-V), CPR activity increased about death. RHS-TM prevented these changes when adminis-
three fold as compared to that in heparin treated rats tered one hour after LPS and A-GBMAb injection and
(Group 3-IV; P  0.01) while thrombus formation was kept all rats alive for more than 24 hours. Because hepa-
inhibited similarly in these two groups. This indicates rin has been the most widely used anticoagulant in the
that a complex of RHS-TM and thrombin effectively clinical setting, the effects of RHS-TM were compared
with heparin. Either 1.0 mg/kg of RHS-TM or the smalleractivated proCPR to CPR (Fig. 6).
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Fig. 7. Injection of carboxypeptidase inhibitor (CPI), an inhibitor of carboxypeptidase R (CPR), increased the infiltration of leukocytes (A) and
neutrophils (B) in the glomerulus. CPI alone did not affect the leukocyte/neutrophil count.
Fig. 8. Immunofluorescent staining for neutrophils in the glomerulus of rats treated with RHS-TM (Group 4-I; A) and RHS-TM  CPI (Group
4-II; B). CPI alone did not increase the neutrophil count in the normal control rats (Group 4-III; C; magnification 400).
dose (83 U/kg/h) of heparin was not sufficient to fully treated with 3.0 mg/kg of RHS-TM, a dose with which
glomerular thrombosis was completely inhibited. As ablock thrombus formation and fibrin deposition, while
3.0 mg/kg of RHS-TM or the larger dose (250 U/kg/h) consequence, heparin induced lung and gastrointestinal
hemorrhage while RHS-TM did not. Therefore, it seemsof heparin completely blocked the changes. One of the
advantages of RHS-TM over heparin is that RHS-TM that RHS-TM might be used in the clinical setting more
conveniently and safely than heparin.is used in a single injection, while heparin must be infused
continuously. Our preliminary experiments showed that In the present model, RHS-TM reduced leukocyte/neu-
trophil infiltration in the glomerulus. Our results indi-a single intravenous injection of heparin (250 U/kg/h)
had no beneficial effects in this model. Furthermore, it cated that besides its anti-coagulant activities, RHS-TM
had anti-inflammatory effects in vivo. Procoagulant ac-induced massive lung hemorrhage (data not shown). In
contrast, RHS-TM, whose half-life is four to five hours tivity and inflammation are two processes that could
promote thrombosis. When procoagulant activity is en-[40], was effective after a single injection. Our data also
suggested that RHS-TM had fewer adverse effects than hanced or endothelial cells damaged by inflammatory
cells (thereby losing some of their anti-thrombotic prop-heparin. In the present experiments the elongation of
prothrombin time seen in the rats treated with the larger erties), thrombosis occurs. Since thrombus formation in
this model is neutrophil dependent [39, 41], one of thedose (250 U/kg/h) of heparin was not observed in rats
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reasons why RHS-TM had potent anti-thrombotic prop- tion were measured. CPR activity was not detected in
plasma of the normal controls or in rats injected witherties with fewer anti-coagulant effects could be related
to this anti-inflammatory action as observed in this study. RHS-TM only. When the thrombus formation is taking
place, endogenous TM on the surface of the endothelialThere are several possible pathways by which RHS-TM
exerts its anti-inflammatory effects. First, the RHS-TM cells forms a complex with thrombin. Since this complex
converts proCPR to CPR, CPR levels are assumed tocan inhibit the inflammatory processes through activa-
tion of protein C. When thrombin forms a complex with increase when thrombi exist. In fact, CPR activity in-
creased in positive control rats in which massive throm-TM, the activation of protein C is 20,000 times greater
than thrombin acting alone [7]. Activated protein C has bus formation occurred. Heparin significantly decreased
the CPR activity probably because it efficiently inhibitedanti-inflammatory effects. It inhibits cell adhesion in
vitro [42]. Moreover, a recent report showed that acti- thrombus formation and decreased the TM-thrombin
complex. Surprisingly, RHS-TM increased CPR activityvated protein C suppresses expression of p50 and p52
nuclear factor-
B (NF-
B) subunits, resulting in a de- while it also inhibited thrombus formation as effectively
as heparin. Heparin inhibits the ability of thrombin tocrease in NF-
B binding. The study further demon-
strated that it blocks expression of downstream NF-
B convert fibrinogen to fibrin, but it does not affect CPR
activity per se. In contrast, RHS-TM not only inhibitsregulated genes [43]. In vivo, activated protein C has a
key role in protecting against disseminated intravascular thrombin’s ability to generate fibrin, but it also effec-
tively activates proCPR. Therefore, we hypothesizedcoagulation [44, 45] and neutrophil-mediated injuries
[46–50], and has recently been reported to improve mor- that RHS-TM attenuated leukocyte/neutrophil infiltra-
tion by enhancing CPR activity in the present model.tality in humans with septic shock [51]. Thus, it is quite
possible that RHS-TM reduced glomerular cell infiltra- This hypothesis was supported by the next experiment
using CPI (experiment 4). CPI, which selectively blockstion via activation of protein C in the present model.
Second, RHS-TM may attenuate the inflammation by the activity of CPR, was administered to rats treated with
RHS-TM following the injection of LPS and A-GMBAb.blocking activation of proteinase-activated receptor-1
(PAR-1, one of the thrombin receptors) on glomerular CPI significantly diminished the inhibitory effect of
RHS-TM on leukocyte/neutrophil infiltration, while CPIendothelial cells. Thrombin is reported to up-regulate
the expression of adhesion molecules such as ICAM-1, alone did not increase the leukocyte/neutrophil counts
in the normal controls. Our results suggested that theP-selectin and E-selectin on endothelial cells [52–54]
presumably by activating PAR-1. It also was reported anti-inflammatory effects of RHS-TM can be attributed,
at least in part, to the activation of proCPR. To furtherthat PAR-1 was partly responsible for the inflammatory
processes in a mouse model of glomerulonephritis [55]. confirm this finding, experiments using recombinant CPR
will be needed. Of note is that our data did not rule outWhen thrombin binds to TM, it loses its ability to activate
PAR-1 [56, 57]. The difference between the anti-inflam- the contribution of protein C or PAR-1. Rather, our study
presented one new pathway by which RHS-TM modu-matory effects of heparin and RHS-TM may be attrib-
uted to the fact that heparin and antithrombin III com- lates the inflammatory process.
Finally, the leukocyte/neutrophil counts in the glomer-plex cannot effectively inactivate clot-bound thrombin,
whereas TM can inactivate it [58]. In the present model uli of positive control rats injected with saline were sig-
nificantly lower than those in rats treated with heparin.RHS-TM may have inhibited PAR-1 by inactivating clot-
bound thrombin resulting in a reduction in glomerular We postulate that the continuous influx of the leukocytes/
neutrophils into the glomeruli may have been inhibitedcell infiltration. Third, RHS-TM may exert its anti-inflam-
matory effects by activating proCPR to CPR. Although once massive thrombus formation occurred and most of
the glomerular capillary lumen was obstructed.thrombin itself can activate proCPR, TM-thrombin com-
plex accelerates this activation 1000-fold [23]. CPR [20] In conclusion, RHS-TM had a greater therapeutic po-
tential with fewer adverse effects as compared to heparindegrades the anaphylatoxins C3a and C5a by cleaving
their terminal arginine residues [25, 26]. Thus, RHS-TM in a rat model of thrombotic glomerulonephritis. The re-
sults showed, for the first time, the contribution of CPRmay have inhibited leukocyte/neutrophil infiltration by
inactivating C3a and C5a. to the anti-inflammatory properties of RHS-TM. RHS-TM
is now under Phase II Clinical Trial for disseminated intra-In the present model, C3 deposition was clearly ob-
served in the glomeruli. Our recent study showed that vascular coagulation in Japan. The present study indicates
that RHS-TM is a new candidate for the treatment of hu-administration of soluble complement receptor 1 (sCR1)
or C5a receptor antagonist suppressed the leukocyte in- man thrombotic microangiopathy and its related disorders.
filtration and attenuated thrombus formation in the pres-
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